Flores-Ramos M

Idioma: Español
Referencias bibliográficas: 62
Paginas: 33-37
Archivo PDF: 86.55 Kb.

RESUMEN

Recientemente, un grupo de autores ha sugerido la existencia de trastornos mentales en la mujer que pueden agruparse como trastornos relacionados a la etapa reproductiva (TRER), caracterizados por el momento en que ocurren (relacionados con el proceso reproductivo), una vulnerabilidad compartida entre éstos y una fisiopatología común. Las manifestaciones clínicas o la sintomatología de los TRER pueden ser diferentes entre mujeres, pero consistentes para cada mujer en particular y siempre están presentes durante los periodos de la vida reproductiva como el embarazo, el posparto, el periodo premenstrual y la perimenopausia. Se sugiere que la fisiopatología de estos trastornos comprende una asociación entre los cambios hormonales y las alteraciones de los neurotransmisores, así como una adaptación anormal a los cambios hormonales en mujeres vulnerables. En el presente trabajo nos proponemos describir las características clínicas y los tratamientos existentes para los TRER, así como el mecanismo fisiopatológico propuesto para ellos y opciones farmacológicas para su tratamiento.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results for the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8-19.

2. Weissman M, Bland R, Joyce P, et al. Sex differences in rates of depression: cross-national perspectives. J Affect Disord. 1993;29:77-84.

3. Caraveo-Anduaga J, Colmenares E, Saldívar G. Morbilidad psiquiátrica en la ciudad de México: prevalencia y comorbilidad a lo largo de la vida. Salud Mental. 1999;22:62-7.

4. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG. Cross-national epidemiology of major depression and bipolardisorder. JAMA. 1996;276(4):293-9.

5. Douma SL, Husband C, O´Donell ME, et al. Estrogen-related mood disorders. Reproductive life cycle factors. Adv Nurs Sci. 2005;28(4): 364-75.

6. Flores-Ramos M, Ontiveros Uribe M. Hormonas gonadales y depresión en la perimenopausia. Rev Colomb Psiquiat. 2008;37(2):236-46.

7. Halbreich U. Women´s Reproductive-Related Disorders (RRDs). J Affect Disord. 2010;122:10-3.

8. Blehar MC. Women´s mental health research: the emergence of a biomedical field. Annu Rev Clin Psychol 2006; 2:135-160.

9. Halbreich U, Borenstein J, Pearlstein T, et al. The prevalence, impairment, impact and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology. 2003;28(S3):1-23.

10. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychological Medicine. 2002;32(1):119-32.

11. Rapkin AJ, Winer SA. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness. Expert Rev Pharmacoeconomics Outcomes Res. 2009;9(2):157-60.

12. Borenstein JE, Dean BB, Endicott J, et al. Health and economic impact of the premenstrual syndrome. J Report Med. 2003;48(7):515-24.

13. Futterman LA, Rapkin AJ. Diagnosis of premenstrual disorders. J Reprod Med. 2006;51(s4):349-58.

14. De Berardis D, Serroni N, Salerno RM, Ferro FM. Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol. Ther Clin Risk Manag. 2007;3(4):585-90.

15. ACOG practice bulletin. Clinical management guidelines for obstetriciangynecologists. Premenstrual syndrome. Obstet Gynecol. 2000;95:1-9.

16. Freeman EW. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs. 2004;18:453-68.

17. Flores-Ramos M, Ontiveros Uribe M, Cortes Sotres J. Comparación entre el tratamiento continuo y el intermitente con citalopram para el trastorno disfórico premenstrual. Salud Mental. 2003;26(3):37-45.

18. American Psychiatric Association. Manual Diagnóstico y Estadístico de los Trastornos Mentales, cuarta edición. Washington, DC, 1994.

19. O´Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Psychol. 1984;93:158-71.

20. Halbreich U, Karkun S. Cross cultural and social diversity of prevalence of postpartum depression and depressive symptoms. J Affective Disord. 2006;91:97-111.

21. Romero-Gutiérrez G, Dueñas de la Rosa EM, Regalado-Cedillo CA, Ponce-Ponce de León AL. Prevalencia de tristeza materna y sus factores asociados. Ginecol Obstet Mex. 2010;78(1):53-7.

22. Alvarado-Esquivel C, Sifuentes-Alvarez A, Estrada-Martínez S, et al. Prevalencia de depresión posnatal en mujeres atendidas en hospitales públicos de Durango, México. Gac Med Mex. 2010;146(1):1-9.

23. Espíndola JG, Morales F, Mota C, et al. Calibración del punto de corte para la escala de depresión perinatal de Edinburgh en pacientes obstétricas del Instituto Nacional de Perinatología. Perinatol Reprod Hum. 2004;18(3):179-86.

24. Reck C, Struben K, Backenstrass M, et al. Prevalence, onset and comorbidity of postpartum anxiety and depressive disorders. Acta Psychiatr Scand. 2008;118:459-68.

25. Figuereido B, Pacheco A, Costa R. Depression during pregnancy and the postpartum period in adolescent and adult Portuguese mothers. Arch Women Ment Health. 2007;10:103-9.

26. Carter W, Grigoriadis S, Ross LE. Relationship distress and depression in postpartum women: literature review and introduction of a conjoint interpersonal psychotherapy intervention. Arch Womens Ment Health. 2010;13(3):279-84.

27. Davey HL, Tough SC, Adair CE, Benzies KM. Risk factors for sub-clinical and major postpartum depression among a community cohort of Canadian women. Matern Child Health J. 2008; DOI: 10.1007/s10995-008-0314-8.

28. Piacentini D, Leveni D, Primerano G, et al. Prevalence and risk factors of postnatal depression among women attending antenatal courses. Epidemiol Psichiatr Soc. 2009;18(3):214-20.

29. McCoy SJ, Beal JM, Saunders B, et al. Risk factors for postpartum depression: a retrospective investigation. J Reprod Med. 2008;53:166-70.

30. Wisner KL, Wheeler SB. Prevention of recurrent postpartum major depression. Hosp Community Psychiatry. 1994;45:1191-6.

31. Seyfried LS, Marcus SM. Postpartum mood disorders. Int Rev Psychiatry. 2003;15:231-42.

32. Buró VK. Mood disorders in women: focus on postpartum. Women´s health in Psychiatry. 2006;2:6-12.

33. Schmidt K, Olesen OV, Jensen PN. Citalopram and breast-feeding. Biol Psychiatry. 2000;47:164-5.

34. Burt VK, Altshuler LL, Rasgon N. Depressive symptoms in the perimenopause: prevalence, assessment, and guidelines for treatment. Harv Rev Psychiatry. 1998;6:121-32.

35. Harlow BL, Wise L, Otto M, et al. Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause. Arch Gen Psychiatry. 2003;60:29-36.

36. Soares CN, Cohen LS. The perimenopause and mood disturbances: an update. CNS Spectr. 2001;6:167-74.

37. Sommer B, Avis N, Meyer P, et al. Attitudes toward menopause and aging across ethnic/racial groups. Psychosom Med. 1999;61(6):868.

38. Depression at perimenopause: more than just hormones. Harvard Women´s Health Watch. 2008;15(10):1-2.

39. Schmidt PJ, Haq N, Rubinow DR. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry. 2004;161(12):2238-44.

40. Rasgon N, Shelton S, Halbreich U. Perimenopausal mental disorders: epidemiology and phenomenology. CNS Spectrums. 2005;10(6):471-8.

41. Stewart DE, Boydell KM. Psychological distress during menopause: associations across the reproductive cycle. Int J Psychiatry Med. 1993;23:157-62.

42. Novaes C, Almeida OP, De Melo NR. Mental health among perimenopausal women attending a menopause clinic: possible association with premenstrual syndrome? Climacteric. 1998;1:264-70.

43. Richards M, Rubinow DR, Daly RC, et al. Premenstrual symptoms and perimenopausal depression. Am J Psychiatry. 2006;163(1):133-7.

44. Flores-Ramos M, Heinze G, Silvestri-Tomassoni R. Association between depressive symptoms and reproductive variables in a group of perimenopausal women attending a menopause clinic in México city. Arch Womens Ment Health; 2010;13(1):99-105.

45. Young EA, Rees Midgley A, Carlson NE, et al. Alteration in the hypothalamic-pituitary-ovarian axis in depressed women. Arch Gen Psychiatry. 2000;57:1157-62.

46. Freeman EW, Sammel MD, Lin H, et al. Symptoms in the menopausal transition: hormone and behavior correlates. Obstet Gynecol. 2008;111(1):127-36.

47. Freeman EW, Sammel MD, Liu L, et al. Hormones and menopausal status as predictors of depression in women transition to menopause. Arch Gen Psychiatry. 2004;61:62-70.

48. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157:1445-52.

49. Berlanga C, Flores-Ramos M. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affective Disord. 2006;95:119-23.

50. Archer DF, DuPont C, Constantine G, Pickar J, Olivier S. Desvenlafaxine succinate (DVS), a novel serotonin and norepinephrine reuptake inhibitor, improves mood and menopausal symptoms in women with hot flushes (HFS) associated with menopause. Fertil Steril. 2007;88(S2):46-62.

51. Joffe H, Soares CN, Petrillo LF, et al. Treatment of depression and menopause related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry. 2007;68:943-50.

52. Soares CD, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58:529-34.

53. Almeida OP, Lautenschlager NT, Vasikaran S. A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: Effect on mood, cognition and quality of life. Neurobiol Aging. 2006;27(1):141-9.

54. Rasgon N, Althuler LL, Fairbanks LA, et al. Estrogen replacement therapy in the treatment for major depressive disorder in perimenopausal women. J Clin Psychiatry. 2002;63 suppl 7:45-8.

55. Soares CN, Zytek B. Reproductive hormone sensitivity and risk for depression across the female cycle: A continuum of vulnerability?. J Psychiatry Neurosci. 2008;33(4):331-43.

56. Morrison JH, Brinton RD, Schmidt PJ, et al. Estrogen, menopause and the aging brain: how basic neuroscience can inform hormone therapy in women. J Neurosci. 2006;26:10332-48.

57. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry. 1998;44:839-50.

58. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev. 1999;20:279-307.

59. Genazzani AR, Bernardi F, Pluchino N, et al. Endocrinology of menopausal transition and its brain implications. CNS Spectr. 2005;10:449-57.

60. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry. 1998;44:839-50.

61. Deecher D, Andree TH, Sloan D, et al. From menarche to menopause: Exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinol. 2008;33:3-17.

62. Halbreich U. Hormones and depression-conceptual transitions. En: Halbreich, U. (Ed.), Hormones and Depression. Nueva York: Raven Press; 1987. p. 1-20.